Creatine Kinase-MB Monoclonal Antibody for Cardiac AMI & Re-Infarction IVD Development
Creatine Kinase-MB (CK-MB) is the cardiac-specific isoform of creatine kinase — an enzyme that catalyses the reversible phosphorylation of creatine by ATP to generate phosphocreatine, the primary immediate energy reservoir in muscle cells. CK exists as three dimeric isoforms: CK-BB (brain), CK-MM (skeletal muscle), and CK-MB (cardiac). The CK-MB isoform is composed of one M-subunit and one B-subunit and has a molecular weight of ~87 kDa.
CK-MB constitutes 15–40% of total CK activity in the myocardium, compared to less than 3% in skeletal muscle, giving CK-MB its cardiac specificity. After acute myocardial infarction (AMI), CK-MB is released from damaged cardiomyocytes into the bloodstream, following a characteristic time course: rise 3–6 hours after onset, peak 12–24 hours, return to baseline 48–72 hours. This shorter half-life compared to cTnI (which remains elevated for 7–14 days) makes CK-MB the preferred marker for detecting re-infarction within the 48–72 hour post-AMI window.
For IVD immunoassay development, CK-MB quantification uses a sandwich format with two monoclonal antibodies targeting distinct, non-overlapping epitopes on the CK-MB heterodimer. Sekbio's CKMB-Ab-S01-120-1M is a mouse anti-human CK-MB monoclonal antibody (Mouse IgG1, ≥90% purity, 4.50 mg/mL) validated for CLIA, LFA, and ELISA cardiac panel development.
Mouse anti-human CK-MB monoclonal antibody for CLIA, LFA, and ELISA cardiac immunoassay development.
| Catalog No. | Product Name | Isotype | Concentration | Purity | Platforms | Storage |
|---|---|---|---|---|---|---|
| CKMB-Ab-S01-120-1M | Mouse Anti-Human CK-MB Monoclonal Antibody | Mouse IgG1 | 4.50 mg/mL | ≥90% SEC-HPLC | LFA / CLIA / ELISA | +2°C to +8°C |
Supplied in 20 mM PB, pH 7.4, 150 mM NaCl. MOQ 1 mg. OEM quantities (10 mg–gram scale) available. Contact info@sekbio.com for bulk pricing, paired antibody recommendations, and lot availability.
High-purity CK-MB antibody optimised for sensitivity and selectivity in cardiac POCT, CLIA, and ELISA platforms.
CKMB-Ab-S01-120-1M is raised against human CK-MB and selected for high specificity for the MB isoform over CK-MM (abundant in skeletal muscle). This selectivity is critical for accurate CK-MB quantification in patients with skeletal muscle injury, rhabdomyolysis, or elevated total CK from non-cardiac causes, where CK-MM background would otherwise confound results.
Affinity-purified from cell culture supernatants with purity ≥90% by SEC-HPLC. High purity reduces non-specific binding in lateral flow nitrocellulose membranes and CLIA microparticle matrices, improving signal-to-noise ratios at the clinical CK-MB cutoff (typically 5–6 ng/mL or 5× upper reference limit for peri-procedural AMI).
CKMB-Ab-S01-120-1M is validated for LFA (lateral flow assay/POCT), CLIA (chemiluminescence immunoassay), and ELISA formats. This broad platform compatibility enables a single antibody supply source for both point-of-care cardiac strip development and hospital laboratory quantitative CLIA analyzer assay development.
Manufactured under ISO 13485 QMS in Shenzhen, China. Each lot is released with full QC including appearance, purity by SEC-HPLC, and molecular weight verification. Certificate of Analysis provided with every shipment. Batch-to-batch consistency essential for stable assay calibration curves in cardiac emergency diagnostics.
CK-MB's 48–72 hour washout (vs 7–14 days for cTnI) makes it uniquely positioned for re-infarction detection. In the context of a patient with known elevated troponin from a primary AMI, a new CK-MB rise after baseline normalisation is a specific indicator of recurrent cardiomyocyte injury, fulfilling ACC/AHA Universal MI Definition Type 4a criteria post-PCI.
Sekbio supplies CK-MB alongside matched H-FABP (S01-FABP series) and cTnI antibody pairs — enabling a single-supplier complete cardiac biomarker panel for OEM POCT lateral flow strip and CLIA kit development. MOQ 1 mg; gram-scale supply for OEM manufacturing. Supports CE and NMPA regulatory submissions.
CK-MB antibody for cardiac emergency diagnostics, AMI diagnosis, re-infarction detection, and peri-procedural MI assessment.
CK-MB is one of the standard cardiac biomarkers for AMI diagnosis in emergency settings. It rises 3–6 hours after myocardial injury, reaches peak levels at 12–24 hours, and normalises by 48–72 hours. CK-MB quantification in both hospital laboratory CLIA analyzers and point-of-care LFA rapid tests supports AMI diagnosis in acute chest pain evaluation. Sekbio's CKMB-Ab-S01-120-1M enables cardiac panel strip and analyzer kit development for both POCT and laboratory settings.
After an initial AMI, cTnI remains elevated for 7–14 days, making recurrent MI difficult to detect by troponin alone. CK-MB, with its 48–72 hour washout, provides a cleaner baseline for detecting a second CK-MB rise indicative of re-infarction. ESC and ACC/AHA guidelines specify that a new CK-MB rise >20% above previous nadir, in the context of clinical and ECG evidence, fulfils criteria for re-infarction. CK-MB assays are therefore a specific clinical need in coronary care unit monitoring kits.
ACC/AHA Fourth Universal Definition of Myocardial Infarction specifies CK-MB as the preferred biomarker for peri-procedural MI: Type 4a (post-PCI) MI is defined by CK-MB >5× upper reference limit (URL) at 24 hours; Type 5 (post-CABG) MI by CK-MB >10× URL. CK-MB's defined molecular weight and isoform specificity makes it the preferred marker for these regulatory definitions, maintaining its clinical utility alongside high-sensitivity troponin in cardiac surgery and interventional cardiology settings.
CK-MB is a standard component of multi-marker cardiac POCT panels (H-FABP + cTnI + CK-MB), providing complementary temporal coverage for early, intermediate, and re-infarction detection. OEM LFA strip and CLIA kit developers can source CK-MB antibody alongside H-FABP (S01-FABP series) and cTnI antibodies from Sekbio as a complete cardiac panel package. Visit our Products page for the full cardiac biomarker portfolio, or contact our team for panel quotes.
Technical and commercial questions from IVD R&D engineers and procurement teams.
CK-MB is the cardiac-specific isoform of creatine kinase, containing one M and one B subunit (87 kDa). Unlike total CK — which includes CK-MM from skeletal muscle and is elevated by exercise, trauma, and rhabdomyolysis — CK-MB constitutes only 15–40% of myocardial CK but <3% of skeletal muscle CK. This tissue distribution gives CK-MB greater cardiac specificity than total CK, enabling detection of myocardial injury even when total CK is elevated from non-cardiac causes.
Sekbio supplies CKMB-Ab-S01-120-1M: mouse anti-human CK-MB monoclonal antibody, isotype Mouse IgG1, concentration 4.50 mg/mL (OD280/1.4), purity ≥90% by SEC-HPLC, buffer 20 mM PB pH 7.4 150 mM NaCl, storage +2°C to +8°C. Available from MOQ 1 mg with full Certificate of Analysis.
CKMB-Ab-S01-120-1M is validated for LFA (lateral flow assay/rapid test), CLIA (chemiluminescence immunoassay), and ELISA (enzyme-linked immunosorbent assay) sandwich formats. The antibody supports both quantitative hospital laboratory CLIA platforms and POCT lateral flow cardiac strip development.
High-sensitivity troponin has largely replaced CK-MB for initial AMI diagnosis, but CK-MB retains specific clinical utility: (1) re-infarction detection within 48–72 hours of primary AMI — CK-MB returns to baseline when troponin remains elevated; (2) peri-procedural MI definition post-PCI (Type 4a: CK-MB >5× URL) and post-CABG (Type 5: CK-MB >10× URL) per ACC/AHA guidelines; (3) certain regulatory and geographic markets where CK-MB-based panels remain standard of care.
CKMB-Ab-S01-120-1M: storage +2°C to +8°C. Shelf life: 3 years from manufacturing date. Avoid multiple freeze/thaw cycles. Supplied in 20 mM PB, pH 7.4, 150 mM NaCl. MOQ 1 mg; OEM quantities from 10 mg to gram scale available.
Yes. Sekbio supplies matched antibody pairs for the complete cardiac emergency panel: CK-MB (CKMB-Ab-S01-120-1M), H-FABP (S01-FABP-1M/2H/2M), and cTnI — enabling single-supplier procurement for multi-marker cardiac POCT strip and CLIA kit development. Contact info@sekbio.com for cardiac panel package pricing, or visit our Platforms page.
Request the full technical datasheet, cardiac panel specifications, or discuss OEM supply with our team.